nach oben

Current Heart Failure Reports

Erschienen in:

14.08.2017 | Management of Heart Failure (T Meyer, Section Editor)

Vitamin D and Heart Failure

verfasst von: D. Marshall Brinkley, Omair M. Ali, Sandip K. Zalawadiya, Thomas J. Wang

Erschienen in: Current Heart Failure Reports | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Vitamin D is principally known for its role in calcium homeostasis, but preclinical studies implicate multiple pathways through which vitamin D may affect cardiovascular function and influence risk for heart failure. Many adults with cardiovascular disease have low vitamin D status, making it a potential therapeutic target. We review the rationale and potential role of vitamin D supplementation in the prevention and treatment of chronic heart failure.

Recent Findings.

Substantial observational evidence has associated low vitamin D status with the risk of heart failure, ventricular remodeling, and clinical outcomes in heart failure, including mortality. However, trials assessing the influence of vitamin D supplementation on surrogate markers and clinical outcomes in heart failure have generally been small and inconclusive.

Summary

There are insufficient data to recommend routine assessment or supplementation of vitamin D for the prevention or treatment of chronic heart failure. Prospective trials powered for clinical outcomes are warranted.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):e147–239. doi:10.1016/j.jacc.2013.05.019.CrossRefPubMed

• Holick MF, Vitamin D. Deficiency. N Engl J Med. 2007;357(3):266–81. doi:10.1056/NEJMra070553. This article reviews vitamin D deficiency, biologic effects, and role of supplementation. CrossRefPubMed

Wang TJ. Vitamin D and cardiovascular disease. Annu Rev Med. 2016;67:261–72. doi:10.1146/annurev-med-051214-025146.CrossRefPubMed

Krul-Poel YH, Ter Wee MM, Lips P, Simsek S. Management of endocrine disease: the effect of vitamin D supplementation on glycaemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Eur J Endocrinol. 2017;176(1):R1–R14. doi:10.1530/EJE-16-0391.CrossRefPubMed

Fleet JC, DeSmet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. The Biochemical journal. 2012;441(1):61–76. doi:10.1042/BJ20110744.CrossRefPubMedPubMedCentral

Hewison M. An update on vitamin D and human immunity. Clin Endocrinol. 2012;76(3):315–25. doi:10.1111/j.1365-2265.2011.04261.x.CrossRef

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30. doi:10.1210/jc.2011-0385.CrossRefPubMed

LeFevre ML. Screening for vitamin D deficiency in adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2015;162(2):133–40. doi:10.7326/m14-2450.CrossRefPubMed

Stumpf WE, Sar M, Reid FA, Tanaka Y, DeLuca HF. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science (New York, NY). 1979;206(4423):1188–90.CrossRef

10.

Chen S, Glenn DJ, Ni W, Grigsby CL, Olsen K, Nishimoto M et al. Expression of the vitamin d receptor is increased in the hypertrophic heart. Hypertension (Dallas, Tex : 1979). 2008;52(6):1106–1112. doi:10.1161/hypertensionaha.108.119602.

11.

O’Connell TD, Berry JE, Jarvis AK, Somerman MJ, Simpson RU. 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Phys. 1997;272(4 Pt 2):H1751–8.

12.

Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest. 1996;97(7):1577–88. doi:10.1172/jci118582.CrossRefPubMedPubMedCentral

13.

Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A. 2007;104(43):16810–5. doi:10.1073/pnas.0611202104.CrossRefPubMedPubMedCentral

14.

Meems LM, Cannon MV, Mahmud H, Voors AA, van Gilst WH, Sillje HH, et al. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol. 2012;132(3–5):282–9. doi:10.1016/j.jsbmb.2012.06.004.CrossRefPubMed

15.

Weishaar RE, Kim SN, Saunders DE, Simpson RU. Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Phys. 1990;258(1 Pt 1):E134–42.

16.

Chen S, Law CS, Grigsby CL, Olsen K, Hong TT, Zhang Y, et al. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation. 2011;124(17):1838–47. doi:10.1161/circulationaha.111.032680.CrossRefPubMedPubMedCentral

17.

Tishkoff DX, Nibbelink KA, Holmberg KH, Dandu L, Simpson RU. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology. 2008;149(2):558–64. doi:10.1210/en.2007-0805.CrossRefPubMed

18.

Zhao G, Simpson RU. Interaction between vitamin D receptor with caveolin-3 and regulation by 1,25-dihydroxyvitamin D3 in adult rat cardiomyocytes. J Steroid Biochem Mol Biol. 2010;121(1–2):159–63. doi:10.1016/j.jsbmb.2010.03.055.CrossRefPubMedPubMedCentral

19.

Green JJ, Robinson DA, Wilson GE, Simpson RU, Westfall MV. Calcitriol modulation of cardiac contractile performance via protein kinase C. J Mol Cell Cardiol. 2006;41(2):350–9. doi:10.1016/j.yjmcc.2006.05.019.CrossRefPubMed

20.

Walters MR, Ilenchuk TT, Claycomb WC. 1,25-Dihydroxyvitamin D3 stimulates 45 Ca2+ uptake by cultured adult rat ventricular cardiac muscle cells. J Biol Chem. 1987;262(6):2536–41.PubMed

21.

Rahman A, Hershey S, Ahmed S, Nibbelink K, Simpson RU. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol. 2007;103(3–5):416–9. doi:10.1016/j.jsbmb.2006.12.081.CrossRefPubMed

22.

Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002;90(5):520–30.CrossRefPubMed

23.

Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229–38. doi:10.1172/jci15219.CrossRefPubMedPubMedCentral

24.

Zhang W, Chen L, Zhang L, Xiao M, Ding J, Goltzman D, et al. Administration of exogenous 1,25(OH)2D3 normalizes overactivation of the central renin-angiotensin system in 1alpha(OH)ase knockout mice. Neurosci Lett. 2015;588:184–9. doi:10.1016/j.neulet.2015.01.013.CrossRefPubMed

25.

Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005;288(1):E125–32. doi:10.1152/ajpendo.00224.2004.CrossRefPubMed

26.

Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008;74(2):170–9. doi:10.1038/ki.2008.101.CrossRefPubMed

27.

Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004;89-90(1–5):387–92. doi:10.1016/j.jsbmb.2004.03.004.CrossRefPubMed

28.

Kasuga H, Hosogane N, Matsuoka K, Mori I, Sakura Y, Shimakawa K, et al. Characterization of transgenic rats constitutively expressing vitamin D-24-hydroxylase gene. Biochem Biophys Res Commun. 2002;297(5):1332–8.CrossRefPubMed

29.

Oh J, Weng S, Felton SK, Bhandare S, Riek A, Butler B, et al. 1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation. 2009;120(8):687–98. doi:10.1161/circulationaha.109.856070.CrossRefPubMedPubMedCentral

30.

Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. Journal of immunology (Baltimore, Md : 1950). 2012;188(5):2127–35. doi:10.4049/jimmunol.1102412.CrossRef

31.

Rigby WF, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest. 1987;79(6):1659–64. doi:10.1172/jci113004.CrossRefPubMedPubMedCentral

32.

Jablonski KL, Chonchol M, Pierce GL, Walker AE, Seals DR. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension (Dallas, Tex : 1979). 2011;57(1):63–69. doi:10.1161/hypertensionaha.110.160929.

33.

Aihara K, Azuma H, Akaike M, Ikeda Y, Yamashita M, Sudo T, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem. 2004;279(34):35798–802. doi:10.1074/jbc.M404865200.CrossRefPubMed

34.

Mitsuhashi T, Morris RC Jr, Ives HE. 1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest. 1991;87(6):1889–95. doi:10.1172/jci115213.CrossRefPubMedPubMedCentral

35.

Mortimer EAJ, Monson RR, MacMahon B. Reduction in mortality from coronary heart disease in men residing at high altitude. N Engl J Med. 1977;296(11):581–5. doi:10.1056/nejm197703172961101.CrossRefPubMed

36.

Fleck A. Latitude and ischaemic heart disease. Lancet. 1989;333(8638):613. doi:10.1016/S0140-6736(89)91634-6.CrossRef

37.

Enquselassie F, Dobson AJ, Alexander HM, Steele PL. Seasons, temperature and coronary disease. Int J Epidemiol. 1993;22(4):632–6.CrossRefPubMed

38.

Douglas AS, Allan TM, Rawles JM. Composition of seasonality of disease. Scott Med J. 1991;36(3):76–82. doi:10.1177/003693309103600304.CrossRefPubMed

39.

Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503.CrossRefPubMed

40.

Giovannucci E, Liu Y, Hollis BW, Rimm EB. A prospective study of 25-hydroxy-vitamin D and risk of myocardial infarction in men. Arch Intern Med. 2008;168(11):1174–80. doi:10.1001/archinte.168.11.1174.CrossRefPubMedPubMedCentral

41.

Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168(12):1340–9. doi:10.1001/archinte.168.12.1340.CrossRefPubMed

42.

Kilkkinen A, Knekt P, Aro A, Rissanen H, Marniemi J, Heliovaara M, et al. Vitamin D status and the risk of cardiovascular disease death. Am J Epidemiol. 2009;170(8):1032–9. doi:10.1093/aje/kwp227.CrossRefPubMed

43.

Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin d levels and the risk of mortality in the general population. Arch Intern Med. 2008;168(15):1629–37. doi:10.1001/archinte.168.15.1629.CrossRefPubMedPubMedCentral

44.

Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. (Dallas, Tex : 1979) 2007;49(5):1063–1069. doi:10.1161/hypertensionaha.107.087288.

45.

Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, et al. Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years: results from a national, population-based prospective study (the Australian diabetes, obesity and lifestyle study). Diabetes Care. 2011;34(5):1133–8. doi:10.2337/dc10-2167.CrossRefPubMedPubMedCentral

46.

Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the third National Health and nutrition examination survey. Diabetes Care. 2004;27(12):2813–8.CrossRefPubMed

47.

Brunvand L, Haga P, Tangsrud SE, Haug E. Congestive heart failure caused by vitamin D deficiency? Acta paediatrica (Oslo, Norway : 1992). 1995;84(1):106–108.

48.

Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol. 2003;41(1):105–12.CrossRefPubMed

49.

Lutsey PL, Michos ED, Misialek JR, Pankow JS, Loehr L, Selvin E, et al. Race and vitamin D binding protein gene polymorphisms modify the association of 25-hydroxyvitamin D and incident heart failure: the atherosclerosis risk in communities study (ARIC). JACC Heart failure. 2015;3(5):347–56. doi:10.1016/j.jchf.2014.11.013.CrossRefPubMedPubMedCentral

50.

Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106(7):963–8. doi:10.1016/j.amjcard.2010.05.027.CrossRefPubMed

51.

Michos ED, Selvin E, Misialek JR, McEvoy JW, Ndumele CE, Folsom AR, et al. 25-hydroxyvitamin D levels and markers of subclinical myocardial damage and wall stress: the atherosclerosis risk in communities study. J Am Heart Assoc. 2016;5(11) doi:10.1161/JAHA.116.003575.

52.

Liu LC, Voors AA, van Veldhuisen DJ, van der Veer E, Belonje AM, Szymanski MK, et al. Vitamin D status and outcomes in heart failure patients. Eur J Heart Fail. 2011;13(6):619–25. doi:10.1093/eurjhf/hfr032.CrossRefPubMed

53.

Wetmore JB, Gadi R, Lee JH, O'Keefe JH, Chan PS, Tang F, et al. Association of 25-hydroxyvitamin D deficiency with NT-pro BNP levels in patients with acute myocardial infarction: a cross-sectional analysis. BMC research notes. 2011;4:542. doi:10.1186/1756-0500-4-542.CrossRefPubMedPubMedCentral

54.

Kestenbaum B, Katz R, de Boer I, Hoofnagle A, Sarnak MJ, Shlipak MG, et al. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol. 2011;58(14):1433–41. doi:10.1016/j.jacc.2011.03.069.CrossRefPubMedPubMedCentral

55.

di Giuseppe R, Buijsse B, Hirche F, Wirth J, Arregui M, Westphal S, et al. Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a prospective, case-cohort study. J Clin Endocrinol Metab. 2014;99(3):947–55. doi:10.1210/jc.2013-2963.CrossRefPubMed

56.

Ameri P, Ronco D, Casu M, Denegri A, Bovio M, Menoni S, et al. High prevalence of vitamin D deficiency and its association with left ventricular dilation: an echocardiography study in elderly patients with chronic heart failure. Nutr Metab Cardiovasc Dis. 2010;20(9):633–40. doi:10.1016/j.numecd.2010.01.002.CrossRefPubMed

57.

Polat V, Bozcali E, Uygun T, Opan S, Karakaya O. Low vitamin D status associated with dilated cardiomyopathy. Int J Clin Exp Med. 2015;8(1):1356–62.PubMedPubMedCentral

58.

Fall T, Shiue I, Bergeå af Geijerstam P, Sundström J, Ärnlöv J, Larsson A, et al. Relations of circulating vitamin D concentrations with left ventricular geometry and function. Eur J Heart Fail 2012;14(9):985–991. doi:10.1093/eurjhf/hfs091.

59.

Ameri P, Canepa M, Milaneschi Y, Spallarossa P, Leoncini G, Giallauria F, et al. Relationship between vitamin D status and left ventricular geometry in a healthy population: results from the Baltimore longitudinal study of aging. J Intern Med. 2013;273(3):253–62. doi:10.1111/joim.12007.CrossRefPubMed

60.

Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393–408. doi:10.1172/jci46122.CrossRefPubMedPubMedCentral

61.

Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119(19):2545–52. doi:10.1161/circulationaha.108.844506.CrossRefPubMedPubMedCentral

62.

• Ky B, Shults J, Keane MG, Sutton MSJ, Wolf M, Feldman HI, et al. FGF23 modifies the relationship between vitamin D and cardiac remodeling. Circulation: Heart Failure. 2013;6(4):817. This paper identified fibroblast growth factor 23 as an effect-modifier of vitamin D status on ventricular remodeling in patients with chronic kidney disease.

63.

Pilz S, März W, Wellnitz B, Seelhorst U, Fahrleitner-Pammer A, Dimai HP, et al. Association of vitamin D Deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. The Journal of Clinical Endocrinology & Metabolism. 2008;93(10):3927–35. doi:10.1210/jc.2008-0784.CrossRef

64.

Schierbeck LL, Jensen TS, Bang U, Jensen G, Køber L, Jensen J-EB. Parathyroid hormone and vitamin D—markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail. 2011;13(6):626–32. doi:10.1093/eurjhf/hfr016.CrossRefPubMed

65.

Zittermann A, Schleithoff SS, Götting C, Dronow O, Fuchs U, Kuhn J, et al. Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail. 2008;10(3):321–7. doi:10.1016/j.ejheart.2008.01.013.CrossRefPubMed

66.

Zittermann A, Fuchs U, Kuhn J, Dreier J, Schulz U, Gummert JF, et al. Parameters of mineral metabolism predict midterm clinical outcome in end-stage heart failure patients. Scand Cardiovasc J. 2011;45(6):342–8. doi:10.3109/14017431.2011.611250.CrossRefPubMed

67.

Boxer RS, Kenny AM, Cheruvu VK, Vest M, Fiutem JJ, Piña II. Serum 25-hydroxyvitamin D concentration is associated with functional capacity in older adults with heart failure. Am Heart J. 2010;160(5):893–9. doi:10.1016/j.ahj.2010.08.004.CrossRefPubMedPubMedCentral

68.

Saponaro F, Marcocci C, Zucchi R, Prontera C, Clerico A, Scalese M, et al. Hypovitaminosis D in patients with heart failure: effects on functional capacity and patients’ survival. Endocrine. 2017:1–8. doi:10.1007/s12020-017-1282-9.

69.

• Scragg R, Stewart AW, Waayer D, et al. Effect of monthly high-dose vitamin d supplementation on cardiovascular disease in the vitamin D assessment study : a randomized clinical trial. JAMA Cardiology. 2017; doi:10.1001/jamacardio.2017.0175. This is the largest RCT examining vitamin D supplementation for prevention of incident CVD or death and it found no significant difference.

70.

• Witte KK, Byrom R, Gierula J, Paton MF, Jamil HA, Lowry JE, et al. Effects of vitamin D on cardiac function in patients with chronic HF: the VINDICATE study. J Am Coll Cardiol. 2016;67(22):2593–603. doi:10.1016/j.jacc.2016.03.508. This RCT found no significant difference in 6-min walk distance with supplementation, but some secondary end points of ventricular function improved. CrossRefPubMedPubMedCentral

71.

• Donneyong MM, Hornung CA, Taylor KC, Baumgartner RN, Myers JA, Eaton CB, et al. Risk of heart failure among postmenopausal women: a secondary analysis of the randomized trial of vitamin D plus calcium of the women’s health initiative. Circulation Heart failure. 2015;8(1):49–56. doi:10.1161/CIRCHEARTFAILURE.114.001738. This post hoc analysis of a large RCT of calcium plus vitamin D in post-menopausal women found a significantly lower rate of incident heart failure with supplementation. CrossRefPubMed

72.

• Ford JA, MacLennan GS, Avenell A, Bolland M, Grey A, Witham M. Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. Am J Clin Nutr. 2014;100(3):746–55. doi:10.3945/ajcn.113.082602. This post hoc analysis of a large RCT in elderly patients with history of fracture found that vitamin D supplementation was associated with lower risk of heart failure. CrossRefPubMed

73.

Dalbeni A, Scaturro G, Degan M, Minuz P, Delva P. Effects of six months of vitamin D supplementation in patients with heart failure: a randomized double-blind controlled trial. Nutrition, metabolism, and cardiovascular diseases: NMCD. 2014;24(8):861–8. doi:10.1016/j.numecd.2014.02.015.CrossRefPubMed

74.

Boxer RS, Hoit BD, Schmotzer BJ, Stefano GT, Gomes A, Negrea L. The effect of vitamin D on aldosterone and health status in patients with heart failure. J Card Fail. 2014;20(5):334–42. doi:10.1016/j.cardfail.2014.01.019.CrossRefPubMedPubMedCentral

75.

Schroten NF, Ruifrok WP, Kleijn L, Dokter MM, Sillje HH, Lambers Heerspink HJ, et al. Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial). Am Heart J. 2013;166(2):357–364 e2. doi:10.1016/j.ahj.2013.05.009.CrossRefPubMed

76.

Boxer RS, Kenny AM, Schmotzer BJ, Vest M, Fiutem JJ, Pina IL. A randomized controlled trial of high dose vitamin D3 in patients with heart failure. JACC Heart Fail. 2013;1(1):84–90. doi:10.1016/j.jchf.2012.11.003.CrossRefPubMedPubMedCentral

77.

Shedeed SA. Vitamin D supplementation in infants with chronic congestive heart failure. Pediatr Cardiol. 2012;33(5):713–9. doi:10.1007/s00246-012-0199-6.CrossRefPubMed

78.

Witham MD, Crighton LJ, Gillespie ND, Struthers AD, McMurdo ME. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circulation Heart failure. 2010;3(2):195–201. doi:10.1161/CIRCHEARTFAILURE.109.907899.CrossRefPubMed

79.

Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83(4):754–9.CrossRefPubMed

80.

Hsia J, Heiss G, Ren H, Allison M, Dolan NC, Greenland P, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation. 2007;115(7):846–54. doi:10.1161/CIRCULATIONAHA.106.673491.CrossRefPubMed

81.

Brazier M, Grados F, Kamel S, Mathieu M, Morel A, Maamer M, et al. Clinical and laboratory safety of one year’s use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2005;27(12):1885–93. doi:10.1016/j.clinthera.2005.12.010.CrossRefPubMed

82.

Beveridge LA, Struthers AD, Khan F, Jorde R, Scragg R, Macdonald HM, et al. Effect of vitamin D supplementation on blood pressure: a systematic review and meta-analysis incorporating individual patient data. JAMA Intern Med. 2015;175(5):745–54. doi:10.1001/jamainternmed.2015.0237.CrossRefPubMed

83.

Arora P, Song Y, Dusek J, Plotnikoff G, Sabatine MS, Cheng S, et al. Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial. Circulation. 2015;131(3):254–62. doi:10.1161/CIRCULATIONAHA.114.011732.CrossRefPubMed

Titel: Vitamin D and Heart Failure
verfasst von: D. Marshall Brinkley
Omair M. Ali
Sandip K. Zalawadiya
Thomas J. Wang
Publikationsdatum: 14.08.2017
Verlag: Springer US
Erschienen in: Current Heart Failure Reports / Ausgabe 5/2017
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-017-0355-7

Neu im Fachgebiet Kardiologie

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Recent Findings.

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Mechanical Circulatory Support for Decompensated Heart Failure

Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction

Erratum to: Updates in Cardiac Resynchronization Therapy for Chronic Heart Failure: Review of Multisite Pacing

Cardiac Palliative Medicine